Baker McKenzie advised Casdin Capital, an investment firm based in New York focused on the life sciences and healthcare industry, on the lead of the oversubscribed extension of the Series B fundraising of $50 million. Further investors in the Series B extension are Danaher Life Sciences, Agilent Technologies, Merck KGaA, Darmstadt, Germany, M. Ventures, LSP, Bpifrance Large Venture Fund and Illumina Ventures.
The proceeds of the extended Series B will enable DNA Script to accelerate the development of its suite of enzymatic DNA synthesis (EDS) technologies — in particular, to support the commercial launch of the company's SYNTAX™ DNA benchtop printer.
A cross-border team of corporate and life sciences lawyers of Baker McKenzie led by Munich based partner Berthold Hummel advised Casdin Capital on all legal aspects of the deal.
Casdin Capital is a hedge fund based in New York with assets under management of around $1.3 billion. It primarily invests in companies operating in the biotechnology, healthcare, life science, information technology and industrial sectors, by partnering with companies and building positions to create value and open new opportunities. Due to decades of participation and practice, Casdin Capital is among the few expert investors in the field.
Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script’s approach leverages nature's billions of years of evolution in synthesizing DNA to enable genome scale synthesis.
Baker McKenzie's recognized international team of life science lawyers regularly advises VC investors, early stage biotech's and big pharma on domestic and international healthcare transactions. Most recently, Baker McKenzie advised BioMedPartners on its Series A Equity Financing of € 10.7 million in Tubulis, CureVac on its strategic mRNA technology collaboration with GSK, LSP Life Science Partners as lead investor on the $38.5 million Series B Equity Financing of DNA Script, Galapagos on its 10 year global research and development collaboration with Gilead, MODAG on a € 12 million Series A Financing and in-licensing of a substance portfolio (Sery), Hitachi Chemical Company on the take-over of German apceth Biopharma, Europe's leading life science fund Forbion as lead investor on a € 17 million Series C Equity Financing of Omeicos Therapeutics, Mundipharma on the sale of its Limburg production site and Hillhouse Capital as co-investor in the € 50 million Series C cross-over financing of Hookipa Biotech.
Legal advisor to Casdin Capital:
Lead: Berthold A. Hummel (Corporate/M&A, lead partner, Munich),
Gautier Valdiguié (Corporate/M&A, managing associate, Paris)
Team: Corporate/M&A: Matthieu Grollemund (partner, Paris) and
Madalina-Georgiana Asandului (associate, Paris)
Tax: Guillaume Le Camus (partner, Paris) and
Robin Gaulier (senior associate, Paris)
Employment: Jeremie Paubel (partner, Paris), Roxane Raissi (associate, Paris)